Gastric Carcinoma

• CLINICAL_TRIALS research · 2026-04-21
  Clinical Trial Update: Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis

  This clinical trial investigates whether microplastic exposure is associated with the pathological progression of gastric carcinogenesis and…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial [Phase 1]

  This is an early-stage (Phase 1) clinical trial evaluating the combination of DS-8201a (trastuzumab deruxtecan) and AZD6738 (camonsertib) fo…

• CLINICAL_TRIALS research · 2026-04-07
  Clinical Trial Update: Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays [NA]

  A clinical trial is evaluating the PAGODA algorithm for adjusting chemotherapy doses to prevent unplanned treatment delays. The study is cur…

• CLINICAL_TRIALS research · 2026-01-21
  Clinical Trial Update: A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. [Phase 3]

  Phase 3 trial evaluating disitamab vedotin with trastuzumab and tislelizumab versus chemotherapy with trastuzumab (with or without pembroliz…

• CLINICAL_TRIALS trial_result · 2025-02-10
  Clinical Trial Update: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer [Phase 1]

  Seagen's SEA-TGT (SGN-TGT) Phase 1 safety study in advanced cancers has been terminated. The study enrolled patients across multiple cancer …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2023-04-10
  Clinical Trial Update: IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 [Phase 1, Phase 2]

  Phase 1/2 trial update for IMM2902 in patients with HER2-expressing advanced solid tumors including advanced solid tumors, advanced lung can…

• CLINICAL_TRIALS trial_result · 2022-11-02
  Clinical Trial Update: Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer [Phase 4]

  Phase 4 clinical trial investigating Yiqi Wenyang Jiedu Prescription for prevention and treatment of postoperative metastasis and recurrence…

• CLINICAL_TRIALS trial_result · 2022-04-06
  Clinical Trial Update: RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer [Phase 2]

  Phase 2 trial update involving RC48 plus AK105 and cisplatin in advanced gastric cancer, including HER2-positive cases.

• CLINICAL_TRIALS trial_result · 2021-07-01
  Clinical Trial Update: Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma [Phase 2]

  Phase 2 trial update evaluating camrelizumab in combination with apatinib for advanced gastric/GEJ adenocarcinoma.

• CLINICAL_TRIALS trial_result · 2021-04-13
  Clinical Trial Update: FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) [Phase 2]

  A Phase 2 clinical trial comparing FOLFOX6 vs mFOLFIRINOX as first-line chemotherapy in metastatic gastric cancer or esophagogastric junctio…

• CLINICAL_TRIALS trial_result · 2021-03-29
  Clinical Trial Update: Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) [Phase 2]

  Phase 2 trial update on personalized immunotherapy-based regimens for recurrent gastric cancer is in early stages with status currently unkn…

• CLINICAL_TRIALS trial_result · 2020-06-22
  Clinical Trial Update: Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer [Phase 2]

  Phase 2 trial updating epacadostat plus pembrolizumab in metastatic or unresectable gastroesophageal junction or gastric cancer (completed; …

• CLINICAL_TRIALS trial_result · 2019-09-17
  Clinical Trial Update: Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection [Phase 3]

  Phase III trial comparing perioperative SOX versus XELOX or SOX alone as post-operative chemotherapy in locally advanced gastric adenocarcin…

• CLINICAL_TRIALS trial_result · 2018-02-27
  Clinical Trial Update: A Study Evaluating MM-310 in Patients With Solid Tumors [Phase 1]

  This update reports a Phase 1 study evaluating MM-310 in patients with solid tumors. The listed indications include urothelial carcinoma, ga…

• CLINICAL_TRIALS trial_result · 2017-12-13
  Clinical Trial Update: Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 clinical trial evaluating pralatrexate and oxaliplatin in unresectable or metastatic esophageal, stomach, or gastroesophageal juncti…

• CLINICAL_TRIALS trial_result · 2014-08-04
  Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 trial results for the Akt inhibitor MK-2206 in advanced gastric and gastroesophageal junction cancers have been posted.

• CLINICAL_TRIALS trial_result · 2014-04-25
  Clinical Trial Update: Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell [Phase 1, Phase 2]

  A Phase 1/2 trial tested neoadjuvant bevacizumab added to DOF versus DOF alone in locally advanced gastric carcinoma. The study has complete…

• CLINICAL_TRIALS trial_result · 2007-01-26
  Clinical Trial Update: A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma [Phase 2]

  This is a Phase 2 clinical trial evaluating pemetrexed plus oxaliplatin as first-line therapy for advanced gastric carcinoma; the study stat…